Modulation of hyperglycemia and oxidative stress by Ezetimibe in Sreptozotocin induce diabetes mellitus rats
karbala journal of pharmaceutical sciences,
Volume 5, Issue 7, Pages 42-50
AbstractDiabetes mellitus (DM) is metabolic diseases characterized by chronic hyperglycemia due to reducing in insulin secretion, insulin function, or both. Ezetimibe is a drug that lowers plasma cholesterol levels. A total of 18 male adult albino rats were used in this study. The animals randomized into 3 groups (of 6 rats each). Rats in first group were injected with citrate buffer only and used as healthy control group. While the rats in other two groups were injected with streptozotocin (STZ) at a dose of 60 mg/kg I.P. and treated as following (for 12 weeks), diabetic control group rats received no treatment. Ezetimibe treated group rats received Ezetimibe 6 mg/kg orally once daily. Every 2 weeks, blood glucose level is measured. At the end of 12th weeks, blood samples were collected to measure the blood glucose level and superoxide dismutase activity, and then the animals were sacrificed. The pancreas was removed for histopathology assessment for the degree of islets damage. In result, Ezetimibe was significantly (P<0.05) lower blood glucose levels in compare with the diabetic controls and the activity of SOD was significantly (P<0.05) elevated in rats treated with Ezetimibe compared with the levels in the healthy and diabetic control rats. Histological studies of the pancreas of diabetic control group revealed moderate pancreas islets damage (atrophy of β-cells and cytoplasm rich by inflammatory cells) in compared to rats received Ezetimibe which have showed normal pancreas appearance to mild pancreas islets damage. In conclusions, the present results suggest that Ezetimibe exhibit hypoglycemic and antioxidant activity in diabetic rats.
- Article View: 73
- PDF Download: 42